logo

Myokardia Inc (MYOK)



Trade MYOK now with
  Date
  Headline
11/4/2020 7:06:59 AM Bristol Myers Squibb, MyoKardia Report Expiration Of HSR Act Waiting Period
10/5/2020 6:33:37 AM Bristol Myers Squibb To Acquire MyoKardia For $13.1 Bln Cash
7/23/2020 4:14:12 PM MyoKardia Says FDA Granted Breakthrough Therapy Designation To Mavacamten
7/21/2020 8:02:13 AM MyoKardia, Fulcrum Therapeutics Enter Strategic Collaboration And License Agreement
7/6/2020 8:08:21 AM MyoKardia Appoints Denelle Waynick As General Counsel And Corporate Secretary
5/11/2020 7:42:05 AM MyoKardia Announces Positive Topline Data From Phase 3 Pivotal EXPLORER-HCM Clinical Trial Of Mavacamten
11/11/2019 7:51:32 AM MyoKardia: Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten Achieved Primary Study
9/10/2019 8:49:15 AM MyoKardia To Evaluate Mavacamten As Alternative To Septal Reduction Therapy In Obstructive Hypertrophic Cardiomyopathy
9/3/2019 8:15:38 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $90 Price Target
8/21/2019 8:36:37 AM MyoKardia Begins Dosing In Phase 1 Clinical Study Of MYK-224 For Hypertrophic Cardiomyopathy
5/13/2019 6:24:17 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $87 Price Target
3/26/2019 8:59:01 PM MyoKardia Prices Public Offering Of 4.925 Mln Shares At $51.00/shr
2/28/2019 8:36:21 AM MyoKardia Q4 Net Loss $15.7 Mln Or $0.39/Shr Vs Loss Of $10.1 Mln Or $0.28/Shr Last Year